Clinicians and scientists working in translational research are invited to explore the importance of therapeutic resistance in the pursuit of personalized medicine. The focus will be on clinical relevance and biomarker discovery.
Discussions will focus on the challenges of therapeutic resistance in personalized medicine, on technical and logistical issues pertaining to personalized medicine, and on creating opportunities for collaborations.
Session 1: Intrinsic vs acquired resistance
Session 2: Tumor heterogeneity
Session 3: Host-tumor interactions
Session 4: Biomarker-driven and biopsy-driven trials
Session 5: Challenges of `omics data
Session 6: Personalized medicine in action
Session 7: New technologies and methodologies
Chair: Dr. Gerald Batist
The deadline for abstracts is February 10, 2012.
Registration will close at a maximum of 250 attendees.
For additional information, please visit: www.resistanceincancer2012com
